

37th Annual Congress of the European Association of Nuclear Medicine

EXAMPLE 19-23, 2024

eanm24.eanm.org

COBRA: Assessment of safety and efficacy of ⁶⁴Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy

Luke Nordquist¹, Eva Lengyelova², Daniel Saltzstein³, David Josephson⁴, Gregg E Franklin⁵, Glynn Morrish², **Othon Gervasio²**, Michelle Parker², Robert Miller², Neal Shore⁶

1. XCancer, US; 2. Clarity Pharmaceuticals, Australia, 3. Urology San Antonio, US; 4. Tower Urology, US; 5. New Mexico Cancer Center, US; 6. Carolina Urologic Research Center, US.

Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting


EANM Disclosure of Interest Statement

1. Othon Gervasio: employee of Clarity Pharmaceuticals Ltd.


Background

- Between 20-40% of patients with prostate cancer (PC) will relapse within 10 years of their primary PC treatment, as identified through rising prostate-specific antigen (PSA) levels¹. Most relapses will occur within 5 years after definitive therapy². Early diagnosis of biochemical recurrence (BCR) with accurate staging is essential to informing optimal treatment decision-making.
- Prostate-specific membrane antigen (PSMA) is used as an imaging target in PC. Current PSMA PET agents have high specificity, but low sensitivity³⁻⁵.
- ⁶⁴Cu-SAR-bisPSMA may offer several advantages over the currently approved PSMA PET agents due to the bivalent structure of SAR-<u>bis</u>PSMA and longer half-life (t_{1/2}) of ⁶⁴Cu (12.7h), compared to monovalent PSMA PET agents utilizing ¹⁸F and ⁶⁸Ga (t_{1/2}<2h)³⁻⁶.
- Clinical evidence has demonstrated 2-3x higher tumor uptake and detection of additional PC lesions using ⁶⁴Cu-SAR-bisPSMA compared to an approved PSMA agent⁶.

^{1.} Ward and Moul. Nat Clin Pract Urol , 2005. 2. Pak et al. Int J Clin Onc. 2019. 3. Locametz FDA approved product information. Accessed on the 6 May 2024. 4. Pylarify FDA approved product information. Accessed on the 6 May 2024. 5. Posluma FDA approved product information Access on the 6 May 2024. 6. Lengyelova & Emmett et al. ASCO, 2023. PET: positron emission tomography.



PROPELLER study: ⁶⁴Cu-SAR-bisPSMA leads to higher uptake, contrast and detection of more lesions vs. ⁶⁸Ga-PSMA-11




Left images: In the PROPELLER study, concordant lesions on ⁶⁴Cu-SAR-bisPSMA (200 MBq) and ⁶⁸Ga-PSMA-11 PET/CT consistently showed higher SUVmax, SUVmean and tumor-to-background ratio with ⁶⁴Cu-SAR-bisPSMA compared to ⁶⁸Ga-PSMA-11 (statistically significant values for all parameters, p<0.001). Interval between scans: 8 days. **Right images:** Readers did not detect uptake in pelvic lymph nodes on the ⁶⁸Ga-PSMA-11 PET/CT (Top). PET/CT demonstrated uptake of ⁶⁴Cu-SAR-bisPSMA (200 MBq, Bottom, arrows) in a left pelvic lymph node according to both readers. PC was confirmed via histopathology. Interval between serial imaging: 7 days. Lengyelova & Emmett et al. ASCO, 2023.



COBRA: Study design

Key Eligibility Criteria

- Confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy
- Suspected recurrence of PC based on rising PSA after definitive therapy based on:
 - Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL post radical prostatectomy; or,
 - 2. Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir post radiation therapy, cryotherapy or brachytherapy
- Negative or equivocal findings for PC on conventional imaging per standard of care (SOC) within 60 days prior to Day 0



PET assessment end Reference Standard: The ⁶⁴Cu-SAR-bisPSMA PET/CT scans were interpreted by 3 independent, blinded, central readers. The findings were assessed against a composite Reference Standard (may consist of histopathology, follow-up SOC imaging and PSA levels) determined by an independent, blinded, central expert panel.

Demographics


Participant Distribution

- 52 were enrolled in the study, received a single dose of
 ⁶⁴Cu-SAR-bisPSMA and were included in the Safety Analysis Set.
- 42 were evaluable for the efficacy endpoints.
- 32 completed the study as planned.
- 20 withdrew from the study early (13 protocol deviation, 4 physician decision, 2 withdrawal by subject, and 1 subject non-compliance).

Characteristics	N = 52 (%)
Age (years): median (range)	69 (53, 85)
Days from PC diagnosis, median (range)	2,547.0 (254, 7952)
ECOG status: n (%) 0 1	49 (94.2) 3 (5.8)
Prior definitive therapy for prostate cancer: n (%) Radical prostatectomy (RP) Radiotherapy (RT) Other (includes RP + RT) Unknown / Not reported	39 (75) 8 (15.4) 2 (3.8) 3 (5.8)
Gleason score: n (%) <8 ≥8	39 (75) 13 (25)
PSA (ng/mL): median (range)	0.9 (0.25 to 17.6)
PSA at baseline, n (%) <0.5 ng/mL 0.5 - <1.0 ng/mL 1.0 - <2.0 ng/mL 2.0 - <5.0 ng/mL ≥5.0 ng/mL SOC scan at baseline, n (%)*	11 (21.2) 17 (32.7) 4 (7.7) 10 (19.2) 10 (19.2)
⁹⁹ mTc-MDP and CT ¹⁸ F-DCFPyL alone ⁶⁸ Ga-PSMA-11 and CT *Full Analysis Set, N=50	48 (96) 1 (2) 1 (2)




Identification of pelvic lesion by ⁶⁴Cu-SAR-bisPSMA (equivocal entry scan using ¹⁸F-DCFPyL, Pylarify[®])



- The ⁶⁴Cu-SAR-bisPSMA imaging led to clinicians changing their intended treatment plan in 48% of the patients
- Only one adverse event was reported to be related to ⁶⁴Cu-SAR-bisPSMA (grade 2 worsening of type II diabetes, resolved)

Identification of lesion in the pelvic region using ⁶⁴Cu-SAR-bisPSMA on next-day imaging (right), negative on same-day imaging (⁶⁴Cu-SAR-bisPSMA; center) and equivocal on screening SOC imaging (¹⁸F-DCFPyL, Pylarify[®]; left). SUVmax of the lesion across scans (arrows and red circles) was 2.3 for ¹⁸F-DCFPyL, 4.3 for same-day ⁶⁴Cu-SAR-bisPSMA and 17.5 for next-day ⁶⁴Cu-SAR-bisPSMA. Top images: PET/CT fusion. Bottom images: PET.

More lesions and more patients with a positive scan were identified by ⁶⁴Cu-SAR-bisPSMA on next-day imaging



- In patients with a negative or equivocal SOC scan, the number of lesions identified by ⁶⁴Cu-SAR-bisPSMA increased from 70 to 129 (sameday vs. next-day imaging; increase of 82%)¹
- 53% of patients had lesions identified by ⁶⁴Cu-SAR-bisPSMA on same-day imaging and 71% of patients on next-day imaging (increase of 34%)²

Next-day imaging identified additional lesions compared to same-day imaging. ⁶⁴Cu-SAR-bisPSMA PET showing positive LNs in the pelvic, extra-pelvic (retroperitoneal) and lesions in the prostatic bed regions.

- Average increase across readers of 82% (from same to next-day imaging). Ranges across the readers for the total number of lesions detected: 53–80 on same-day vs. 82–153 on next-day imaging. Full Analysis Set: 42 patients.
- Average increase across readers of 34% (from same to next-day imaging) Detection rate (DR) range across the readers on same-day imaging was 44– 58% (95% CI 30–71.8), increasing on next-day imaging to 58–80% (95% CI 43.2–90). 3. All images are displayed at Maximum Intensity Projection.

Key Efficacy Results: DR, CDR, PPV

Comparison of same-day vs. next-day imaging (*average across readers*)


- DR increased from 53% to 71%
- CDR increased from 23% to 31%
- Region level PPV remained relatively stable at 42% and 39%
- Specificity of PC detection in the pelvic lymph nodes remained high at 95% and 85%

The CDR and PPV results were substantially impacted by the large number of lesions that were detected, but unable to be biopsied (not clinically appropriate), coupled with the low sensitivity of the SOC scans


⁶⁴ Cu-SAR-bisPSMA PET	Same-day imaging	Next-day imaging
Patient Level DR (n=50)		
Positive patients, n (%)	22-29 (44-58)	29-40 (58-80)
Equivocal patients, n (%)	2-6 (4-12)	0-7 (0-14)
Negative patients, n (%)	15-25 (30-50)	6-21 (12-42)
Patient Level CDR (n=42)		
TP patients, n (%)	8-11 (19.0-26.2)	11-14 (26.2-33.3)
CDR % (95% CI)	19.0-26.2 (8.6-42.0)	26.2-33.3 (13.9-49.5)
Region Level PPV (n=42)		
TP regions, n (%)	9-14 (4.6-7.2)	13-17 (6.7-8.8)
FP regions, n (%)	14-20 (7.2-10.3)	17-35 (8.7-18.0)
PPV % (95% CI)	39.1-44.8 (19.7-64.3)	32.7-43.3 (20.3-62.6)

The table shows the ranges across the 3 readers. Specificity rates (reported as a range with 95% Cl in %): Same-day imaging – pelvic region 93.8 to 96.9% (79.2 to 99.9), extra-pelvic region 93.9 to 97% (79.8 to 99.9), bone region 91.9 to 94.6% (78.1 to 99.3); next-day imaging – pelvic region 81.3 to 87.9% (63.6 to 96.6), extra-pelvic region 90.9 to 97% (75.7 to 99.9), bone region 78.4 to 97.3% (61.8 to 99.9).

Higher uptake and contrast in lesions on next-day vs. same-day imaging allows for detection of lesions in the 2-millimeter range



TBR of lesions detected by ⁶⁴Cu-SAR-bisPSMA



>80% increase in mean SUVmean and SUVmax

>5x increase in mean TBR (same-day vs. next-day imaging)

Figure 1. Pelvic lymph nodes showing uptake of ⁶⁴Cu-SAR-bisPSMA on next-day imaging. Blue arrow: lymph node size 3.8 mm x 4.4 mm, SUVmean 20.6, SUVmax 22.1 and TBR 130.1. Green arrow: lymph node size also 3.8 mm x 4.4 mm, SUVmean 11.9. SUVmax 12.8 and TBR 75.3. Red arrow: lymph node showing ⁶⁴Cu-SAR-bisPSMA uptake (>5 mm). Maximum Intensity Projection.

Figure 2. SUVmean/max and TBR comparing same-day and next-day imaging. Average increase across 3 readers. SUVmean: mean standardised uptake value. SUVmax: maximum standardised uptake value. TBR: tumour-to-background ratio. The SUVmax, SUVmean and TBR were assessed in up to 25 lesions per patient on each ⁶⁴Cu-SAR-bisPSMA scan. Ranges across the readers for same-day and next-day imaging, respectively: SUVmean 6.6-9.9 and 14.7-15.8; SUVmax 13.9-14.0 and 22.2-33.4; TBR 23.2-25.4 and 118.1-181.7. TBR = SUVmax of the lesions / SUVmean of the gluteus region.

Conclusions

- 1. ⁶⁴Cu-SAR-bisPSMA was deemed safe and effective in detecting PC lesions in patients with BCR.
- **2. More lesions, regions and more patients** with a positive scan were identified on ⁶⁴Cu-SAR-bisPSMA PET compared to SOC scans, and on next-day vs. same-day imaging.
- **3. Higher uptake and TBR** observed in lesions detected by ⁶⁴Cu-SAR-bisPSMA on **next-day imaging** compared to **same-day imaging**.
- 4. ⁶⁴Cu-SAR-bisPSMA PET results led to clinicians changing the **intended treatment plan in ~50% of the patients**.
- 5. A phase 3 study investigating ⁶⁴Cu-SAR-bisPSMA in BCR is currently in development.

